SCHEMBL15978466

SCHEMBL15978466

Cc1c(N)c(Cl)nc2ccccc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.52
HSD17B10 Q99714 5/20 0.52
KDM4E B2RXH2 5/20 0.52
HPGD P15428 4/20 0.52
ACHE P22303 4/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
GLA P06280 2/20 0.52
CASP1 P29466 2/20 0.52
CASP7 P55210 2/20 0.52
MAOA P21397 2/20 0.52
TDP1 Q9NUW8 2/20 0.52
CHRM2 P08172 2/20 0.52
ADRA2A P08913 2/20 0.52
ADORA3 P0DMS8 2/20 0.52
CHRM1 P11229 2/20 0.52
SLC6A2 P23975 2/20 0.52
OPRM1 P35372 2/20 0.52
KCNH2 Q12809 2/20 0.52
NQO2 P16083 1/20 0.52
DRD1 P21728 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30583435 0.82 ACHE (0.64) ALDH1A1HSD17B10KDM4EHPGDACHE
SCHEMBL27943843 0.82 TDP1 (0.52) ALDH1A1HSD17B10KDM4EHPGDACHE
SCHEMBL210949 0.82 ACHE (0.64) ALDH1A1HSD17B10KDM4EHPGDACHE
SCHEMBL5469806 0.80 MAOA (0.56) ALDH1A1HSD17B10KDM4EHPGDACHE
SCHEMBL28042218 0.80 ALDH1A1 (0.62) ALDH1A1HSD17B10KDM4EHPGDACHE
Hydrochloric Acid SCHEMBL843193 0.80 RAB9A (0.65) ALDH1A1HSD17B10KDM4EHPGDACHE
SCHEMBL12874595 0.80 MAOA (0.61) ALDH1A1HSD17B10KDM4EHPGDACHE
SCHEMBL30631523 0.77 MAOA (0.47) ALDH1A1HSD17B10KDM4EHPGDMAOA
SCHEMBL28878310 0.77 ALDH1A1 (0.52) ALDH1A1HSD17B10KDM4EHPGDACHE
SCHEMBL27549449 0.77 ALDH1A1 (0.52) ALDH1A1HSD17B10KDM4EHPGDACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3950687-A1 INDUSTRIAL METHOD FOR SYNTHESISING IMIQUIMOD FROM QUINOLINE-2,4-DIOL APPLICABLE TO THE PHARMACEUTICAL USE THEREOF PHV Pharma (FR) 2022-02-09 EP disclosed
US-9873694-B2 Imidazole quinoline-based immune system modulators JANUS BIOTHERAPEUTICS, INC. (US) 2018-01-23 US disclosed
US-20140242121-A1 NOVEL IMIDAZOLE QUINOLINE-BASED IMMUNE SYSTEM MODULATORS JANUS BIOTHERAPEUTICS, INC. (US) 2014-08-28 US disclosed
CN-101370765-B Method for selectively producing primary amine SUMITOMO CHEMICAL CO 2013-03-13 CN disclosed
CN-101370765-A Method for selectively producing primary amine SUMITOMO CHEMICAL CO (JP) 2009-02-18 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140242121-A1 NOVEL IMIDAZOLE QUINOLINE-BASED IMMUNE SYSTEM MODULATORS IRF3, HLA-DRB1, IFNG ALDH1A1 2789/4885HSD17B10 3710/4885KDM4E 1584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.